Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,034,555
  • Shares Outstanding, K 183,801
  • Annual Sales, $ 152,920 K
  • Annual Income, $ -444,440 K
  • 60-Month Beta 1.46
  • Price/Sales 19.54
  • Price/Cash Flow N/A
  • Price/Book 3.22
Trade NKTR with:

Options Overview

Details
  • Implied Volatility 55.12%
  • Historical Volatility 28.73%
  • IV Percentile 13%
  • IV Rank 16.56%
  • IV High 153.15% on 10/14/20
  • IV Low 35.66% on 06/24/21
  • Put/Call Vol Ratio 0.40
  • Today's Volume 849
  • Volume Avg (30-Day) 701
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,631
  • Open Int (30-Day) 7,454

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.80
  • Number of Estimates 8
  • High Estimate -0.73
  • Low Estimate -0.83
  • Prior Year -0.61
  • Growth Rate Est. (year over year) -31.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.92 +27.79%
on 08/20/21
16.73 -1.31%
on 09/14/21
+2.84 (+20.78%)
since 08/17/21
3-Month
12.92 +27.79%
on 08/20/21
18.12 -8.89%
on 06/28/21
-0.73 (-4.23%)
since 06/17/21
52-Week
12.92 +27.79%
on 08/20/21
26.75 -38.28%
on 02/17/21
-3.83 (-18.83%)
since 09/17/20

Most Recent Stories

More News
RedHill Reports Second Quarter 2021 Results

(Nasdaq:RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter ended June 30, 2021.

NKTR : 16.51 (+1.54%)
RDHL : 4.89 (+1.45%)
Opioid Induced Constipation (OIC) Drugs Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2026

Report Published by Introspective Market Research on Opioid Induced Constipation (OIC) Drugs Market provides detailed description about the collaborations, deals, designations, patent information etc....

AGN : 193.02 (+0.02%)
DSNKY : 25.5100 (-0.12%)
IRWD : 12.35 (+2.24%)
NKTR : 16.51 (+1.54%)
OPHLF : 22.5000 (unch)
PGNX : 4.10 (-9.39%)
TKPYY : 16.5900 (-0.90%)
TBPH : 7.11 (+3.64%)
VRX.TO : 30.80 (-3.33%)
Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track

Nektar (NKTR) reports encouraging second-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

BMY : 61.31 (+0.13%)
MRK : 71.68 (-0.40%)
LLY : 230.10 (-0.41%)
NKTR : 16.51 (+1.54%)
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 4.17% and 7.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NKTR : 16.51 (+1.54%)
Nektar Therapeutics Reports Second Quarter 2021 Financial Results

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended .

NKTR : 16.51 (+1.54%)
What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

IRWD : 12.35 (+2.24%)
PRGO : 43.94 (-0.77%)
NKTR : 16.51 (+1.54%)
PETQ : 24.98 (-0.99%)
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based financial markets. Howard...

NKTR : 16.51 (+1.54%)
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed , M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have...

NKTR : 16.51 (+1.54%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 126.79 (-0.51%)
ACRX : 1.0200 (unch)
ACOR : 4.73 (+0.85%)
AXSM : 29.72 (+4.17%)
BAYRY : 13.2900 (-1.41%)
BDRFF : 121.4335 (-2.23%)
BDSI : 3.99 (-2.44%)
BMY : 61.31 (+0.13%)
COLL : 19.83 (+0.81%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3100 (+6.50%)
EGLT : 0.0315 (-63.37%)
LLY : 230.10 (-0.41%)
FLXN : 6.23 (-3.41%)
GLPG : 55.64 (+0.63%)
HRTX : 12.10 (+2.80%)
KMPH : 9.08 (+1.57%)
MRK : 71.68 (-0.40%)
MESO : 6.17 (-2.83%)
NKTR : 16.51 (+1.54%)
NVS : 83.48 (-1.07%)
ORXOY : 4.1300 (+7.55%)
PFE : 43.89 (-1.30%)
REGN : 651.88 (-0.20%)
VRX.TO : 30.80 (-3.33%)
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

BMY : 61.31 (+0.13%)
EXEL : 20.72 (+0.88%)
NKTR : 16.51 (+1.54%)
RGEN : 306.90 (+2.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

3rd Resistance Point 17.39
2nd Resistance Point 16.98
1st Resistance Point 16.75
Last Price 16.51
1st Support Level 16.11
2nd Support Level 15.70
3rd Support Level 15.47

See More

52-Week High 26.75
Fibonacci 61.8% 21.47
Fibonacci 50% 19.83
Fibonacci 38.2% 18.20
Last Price 16.51
52-Week Low 12.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar